Global Patterns in Access and Benefit-Sharing: A Comprehensive Review of National Policies

Gunnar V Ljungqvist,Ciara M Weets,Tess Stevens,Hailey Robertson,Ryan Zimmerman,Ellie Graeden,Rebecca Katz
DOI: https://doi.org/10.1101/2024.07.12.24310347
2024-07-14
Abstract:Introduction The goal of Access and Benefit-Sharing (ABS) in global health governance is to ensure that countries that provide genetic resources, including pathogens, receive equitable access to the benefits derived from their use. The increasing availability of genetic resource digitalization has brought this issue to the forefront of discussions on global health security and health equity. While originally conceptualized in supranational agreements, implementation of these treaties requires national-level legislation in each country. This work represents the first comprehensive effort to map ABS policies in all 193 United Nations member states. Methods We conducted a standardized review of the legislation for 193 United Nations Member States across 3 global legal databases (ABS Clearing House, WIPOLEX, and FAOLEX), national legal databases, and a systematic Google search. Legally-enforceable policies were identified, and data was extracted across the following 8 aspects of ABS legislation: Scope of Legislation, Digital Sequence Information, Access to Resources, Prior Informed Consent, Contractual Terms, Benefit-Sharing, Compliance, and Legal Sanctions. Results We found that 104 countries have legally-enforceable policies on ABS, with 92 countries having ABS policies relevant to microorganisms. Of these, 74 countries have chosen to restrict access to their domestic pathogens, and 53 have chosen to link access to pathogenic resources with an obligation to share benefits. Altogether 60 countries have a codified position on Digital Sequence Information (DSI) with regard to ABS: 20 have included it, 34 have excluded it, and 6 have ambiguous wording. WHO regional coverage of ABS or DSI policy ranged from 28% (3/11) of countries in the Eastern Mediterranean Region, to 62% (33/54) of countries in the European Region. Conclusion These findings highlight the heterogeneity found in the global policy landscape as it pertains to ABS, and provide data to inform future agreements and research efforts related to ABS.
Public and Global Health
What problem does this paper attempt to address?